SCHEMBL894822

SCHEMBL894822

CC(C)(C)OC(=O)NCCNCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.58
IDO1 P14902 1/20 0.56
CA1 P00915 2/20 0.56
CA12 O43570 1/20 0.56
CA7 P43166 1/20 0.56
CA14 Q9ULX7 1/20 0.56
PDCD1 Q15116 1/20 0.53
CD274 Q9NZQ7 1/20 0.53
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MALT1 Q9UDY8 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.49
SIGMAR1 Q99720 2/20 0.48
CTSK P43235 1/20 0.48
BCHE P06276 1/20 0.48
SYK P43405 1/20 0.48
CYP3A4 P08684 1/20 0.47
KDM4E B2RXH2 1/20 0.47
MITF O75030 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22605044 1.00 ATM (0.58) ATMIDO1CA1CA12CA7
SCHEMBL13426175 0.91 ATM (0.55) ATMIDO1CA1CA12CA7
SCHEMBL6559442 0.91 ATM (0.55) ATMIDO1CA1CA12CA7
SCHEMBL16151782 0.90 MAOA (0.56) ATMIDO1CA1CA12CA7
SCHEMBL22452275 0.89 PPARG (0.52) ATMIDO1CA1CA12CA7
SCHEMBL4709745 0.87 PDCD1 (0.52) ATMIDO1CA1PDCD1CD274
SCHEMBL21066539 0.87 PDCD1 (0.49) ATMIDO1CA1CA12CA7
SCHEMBL8399561 0.87 IDO1 (0.55) ATMIDO1CA1CA12CA7
SCHEMBL22783855 0.86 KDM4E (0.53) ATMIDO1CA1CA12CA7
SCHEMBL4704671 0.86 IDO1 (0.50) ATMIDO1CA1CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4714499-A2 POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF Jiangsu NHWA Pharmaceutical Co., Ltd (CN) 2026-03-25 EP disclosed
US-20250230129-A1 POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF JIANGSU NHWA PHARMACEUTICAL CO., LTD (CN) 2025-07-17 US disclosed
EP-4497754-A1 POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF Jiangsu NHWA Pharmaceutical Co., Ltd (CN) 2025-01-29 EP disclosed
US-12157731-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2024-12-03 US disclosed
US-20240309003-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2024-09-19 US disclosed
US-20240293424-A1 CARNITINE-PALMITOYL-TRANSFERASE-1 (CPT-1) INHIBITORS FOR USE IN A METHOD OF PREVENTING OR TREATING SEPSIS IN A MAMMALIAN SUBJECT 2N PHARMA APS (DK) 2024-09-05 US disclosed
US-20240246957-A1 Diazepane Derivatives, Processes for their Preparation, and Uses thereof for the Amelioration, Prevention and/or Treatment of Mental and Neurological Diseases 2N PHARMA APS (DK) 2024-07-25 US disclosed
EP-4370129-A1 CARNITINE-PALMITOYL-TRANSFERASE-1 (CPT-1) INHIBITORS FOR USE IN A METHOD OF PREVENTING OR TREATING SEPSIS IN A MAMMALIAN SUBJECT 2N Pharma ApS (DK) 2024-05-22 EP disclosed
EP-4334313-A1 DIAZEPANE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND USES THEREOF FOR THE AMELIORATION, PREVENTION AND/OR TREATMENT OF MENTAL AND NEUROLOGICAL DISEASES 2N Pharma ApS (DK) 2024-03-13 EP disclosed
EP-4334295-A2 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE Vigil Neuoscience, Inc. (US) 2024-03-13 EP disclosed
US-20080167491-A1 T-butoxycarbonylaminoethylamine for the Synthesis of PNA Monomer Units, Amino Acid Derivatives, Intermediates Thereof, and Processes for Productions of Them CREDIA JAPAN CO., LTD. (JP) 2008-07-10 US disclosed
US-20080167491-A1 T-butoxycarbonylaminoethylamine for the Synthesis of PNA Monomer Units, Amino Acid Derivatives, Intermediates Thereof, and Processes for Productions of Them CREDIA JAPAN CO., LTD. (JP) 2008-07-10 US disclosed
US-7351852-B2 Simple and efficient preparation of an amino acid, alpha-tertiary-butoxycarbonylaminoethylamino-),alpha-(alkyl-)acetic acid; used to prepare peptide nucleic acids (PNA) including those having photosensitive functional groups; reduction step of benzyloxycarbonyl- omega -amino acid derivatives CREDIA JAPAN CO., LTD. (JP) 2008-04-01 US disclosed
US-7351852-B2 Simple and efficient preparation of an amino acid, alpha-tertiary-butoxycarbonylaminoethylamino-),alpha-(alkyl-)acetic acid; used to prepare peptide nucleic acids (PNA) including those having photosensitive functional groups; reduction step of benzyloxycarbonyl- omega -amino acid derivatives CREDIA JAPAN CO., LTD. (JP) 2008-04-01 US disclosed
US-20070167457-A1 N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC 2007-07-19 US disclosed
WO-2007017092-A1 SUBSTITUTED 4-BENZYLOXY-BENZOIC ACID AMIDE DERIVATIVES BAYER HEALTHCARE AG (DE) 2007-02-15 WO disclosed
US-7166608-B2 N-aroyl piperazine derivatives as orexin receptor antagonists SMITHKLINE BEECHAM P.L.C. (GB) 2007-01-23 US disclosed
US-20040242575-A1 N-aroyl piperazine derivatives as orexin receptor antagonists SMITHKLINE BEECHAM P.L.C. (GB) 2004-12-02 US disclosed
EP-1434583-A1 N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2004-07-07 EP disclosed
WO-2003032991-A1 N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240293424-A1 CARNITINE-PALMITOYL-TRANSFERASE-1 (CPT-1) INHIBITORS FOR USE IN A METHOD OF PREVENTING OR TREATING SEPSIS IN A MAMMALIAN SUBJECT CPT1A, CPT1B, CPT2 ATM 2677/4885IDO1 1152/4885CA1 2879/4885
US-20250230129-A1 POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF ADCYAP1R1, PAICS, AGPS ATM 4263/4885IDO1 1513/4885CA1 1076/4885
US-20040242575-A1 N-aroyl piperazine derivatives as orexin receptor antagonists HCRTR2, HCRTR1, CNR1 ATM 4720/4885IDO1 300/4885CA1 1454/4885
US-20070167457-A1 N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPSR1 ATM 4701/4885IDO1 527/4885CA1 1382/4885
US-20080167491-A1 T-butoxycarbonylaminoethylamine for the Synthesis of PNA Monomer Units, Amino Acid Derivatives, Intermediates Thereof, and Processes for Productions of Them BCAT1, BCAT2, RNGTT ATM 1697/4885IDO1 1650/4885CA1 1059/4885
US-12157731-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 ATM 2461/4885IDO1 4758/4885CA1 4317/4885
US-20240309003-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 ATM 1627/4885IDO1 881/4885CA1 3334/4885
US-20240246957-A1 Diazepane Derivatives, Processes for their Preparation, and Uses thereof for the Amelioration, Prevention and/or Treatment of Mental and Neurological Diseases SLC6A1, H1-3, GRIK3 ATM 4353/4885IDO1 580/4885CA1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.